{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:30:01Z","timestamp":1773271801192,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T00:00:00Z","timestamp":1202342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00520-007-0399-4","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T10:40:47Z","timestamp":1202294447000},"page":"1117-1123","source":"Crossref","is-referenced-by-count":20,"title":["Established and potential therapeutic applications of octreotide in palliative care"],"prefix":"10.1007","volume":"16","author":[{"given":"Eric E.","family":"Prommer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,7]]},"reference":[{"issue":"3","key":"399_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20(3):157\u2013198","journal-title":"Front Neuroendocrinol"},{"issue":"24","key":"399_CR2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","volume":"309","author":"S Reichlin","year":"1983","unstructured":"Reichlin S (1983) Somatostatin. N Engl J Med 309(24):1495\u20131501","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"399_CR3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000201084","volume":"54","author":"RD Hurst","year":"1993","unstructured":"Hurst RD, Modlin IM (1993) Use of radiolabeled somatostatin analogs in the identification and treatment of somatostatin receptor-bearing tumors. Digestion 54(Suppl 1):88\u201391","journal-title":"Digestion"},{"issue":"12","key":"399_CR4","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1046\/j.1460-9568.1998.00386.x","volume":"10","author":"S Schulz","year":"1998","unstructured":"Schulz S, Schreff M, Schmidt H, Handel M, Przewlocki R, Hollt V (1998) Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. Eur J Neurosci 10(12):3700\u20133708","journal-title":"Eur J Neurosci"},{"issue":"5","key":"399_CR5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0196-9781(96)00112-X","volume":"17","author":"RJ Traub","year":"1996","unstructured":"Traub RJ, Brozoski D (1996) Anti-somatostatin antisera, but neither a somatostatin agonist (octreotide) nor antagonist (CYCAM), attenuates hyperalgesia in the rat. Peptides 17(5):769\u2013773","journal-title":"Peptides"},{"issue":"Pt 1","key":"399_CR6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1113\/jphysiol.2002.025890","volume":"546","author":"S Peineau","year":"2003","unstructured":"Peineau S, Potier B, Petit F, Dournaud P, Epelbaum J, Gardette R (2003) AMPA-sst2 somatostatin receptor interaction in rat hypothalamus requires activation of NMDA and\/or metabotropic glutamate receptors and depends on intracellular calcium. J Physiol 546(Pt 1):101\u2013117","journal-title":"J Physiol"},{"issue":"6","key":"399_CR7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0885-3924(94)90178-3","volume":"9","author":"S Mercadante","year":"1994","unstructured":"Mercadante S (1994) The role of octreotide in palliative care. J Pain Symptom Manage 9(6):406\u2013411","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"399_CR8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2036.2002.01228.x","volume":"16","author":"C Hogenauer","year":"2002","unstructured":"Hogenauer C, Aichbichler B, Santa AC, Porter J, Fordtran J (2002) Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo. Aliment Pharmacol Ther 16(4):769\u2013777","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"399_CR9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","volume":"334","author":"SW Lamberts","year":"1996","unstructured":"Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334(4):246\u2013254","journal-title":"N Engl J Med"},{"key":"399_CR10","volume-title":"The syringe driver","author":"A Dickman","year":"2002","unstructured":"Dickman A, Littlewood C, Varga J (2002) The syringe driver. Oxford University Press, Oxford"},{"key":"399_CR11","unstructured":"Micromedex Healthcare Series: Octreotide. 2005."},{"key":"399_CR12","unstructured":"Product Information: Sandostatin (octreotide). Novartis Pharmaceuticals Corp, East Hanover, NJ. 2002."},{"key":"399_CR13","unstructured":"Product Information: Sandostatin LAR Depot Novartis Pharmaceuticals Corp, East Hanover, NJ. 2007."},{"issue":"4","key":"399_CR14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1440-1797.2005.00427.x","volume":"10","author":"PH Lee","year":"2005","unstructured":"Lee PH, Lin CL, Lai PC, Yang CW (2005) Octreotide therapy for chylous ascites in a chronic dialysis patient. Nephrology (Carlton) 10(4):344\u2013347","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"399_CR15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2177\/jsci.28.56","volume":"28","author":"C Suzuki","year":"2005","unstructured":"Suzuki C, Ohara M, Yamamoto M et al (2005) A case of scleroderma-polymyositis overlap syndrome in which octreotide exacerbated abdominal symptoms. Nihon Rinsho Meneki Gakkai Kaishi 28(1):56\u201361","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"4","key":"399_CR16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0002-9629(15)40844-4","volume":"320","author":"K Demirkan","year":"2000","unstructured":"Demirkan K, Fleckenstein JF, Self TH (2000) Thrombocytopenia associated with octreotide. Am J Med Sci 320(4):296\u2013297","journal-title":"Am J Med Sci"},{"issue":"1","key":"399_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00007611-199001000-00035","volume":"83","author":"WT Hanna","year":"1990","unstructured":"Hanna WT, Maull KI (1990) Sandostatin-induced thrombocytopenia. South Med J 83(1):77","journal-title":"South Med J"},{"issue":"2","key":"399_CR18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1213\/01.ANE.0000097170.27056.08","volume":"98","author":"JA Dilger","year":"2004","unstructured":"Dilger JA, Rho EH, Que FG, Sprung J (2004) Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. Anesth Analg 98(2):318\u201320","journal-title":"Anesth Analg"},{"issue":"10","key":"399_CR19","first-page":"671","volume":"320","author":"AM Landolt","year":"1989","unstructured":"Landolt AM, Schmid J, Wimpfheimer C, Karlsson ER, Boerlin V (1989) Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. N Engl J Med 320(10):671\u2013672","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"399_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0012.1995.tb00324.x","volume":"9","author":"AJ Morton","year":"1995","unstructured":"Morton AJ, Durrant ST (1995) Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation. Clin Transplant 9(3 Pt 1):205\u2013208","journal-title":"Clin Transplant"},{"issue":"3","key":"399_CR21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s005200050283","volume":"8","author":"S Mercadante","year":"2000","unstructured":"Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8(3):188\u2013191","journal-title":"Support Care Cancer"},{"issue":"2B","key":"399_CR22","first-page":"1187","volume":"22","author":"K Mystakidou","year":"2002","unstructured":"Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L (2002) Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res 22(2B):1187\u20131192","journal-title":"Anticancer Res"},{"issue":"1","key":"399_CR23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0885-3924(99)00147-5","volume":"19","author":"C Ripamonti","year":"2000","unstructured":"Ripamonti C, Mercadante S, Groff L, Zecca E, De CF, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 19(1):23\u201334","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"399_CR24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpainsymman.2005.05.018","volume":"30","author":"UA Matulonis","year":"2005","unstructured":"Matulonis UA, Seiden MV, Roche M et al (2005) Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 30(6):563\u2013569","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"399_CR25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpainsymman.2004.01.007","volume":"28","author":"S Mercadante","year":"2004","unstructured":"Mercadante S, Ferrera P, Villari P, Marrazzo A (2004) Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage 28(4):412\u2013416","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"399_CR26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.1993.11.1.148","volume":"11","author":"S Cascinu","year":"1993","unstructured":"Cascinu S, Fedeli A, Fedeli SL, Catalano G (1993) Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 11(1):148\u2013151","journal-title":"J Clin Oncol"},{"issue":"4","key":"399_CR27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00001813-199308000-00004","volume":"4","author":"V Gebbia","year":"1993","unstructured":"Gebbia V, Carreca I, Testa A et al (1993) Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 4(4):443\u2013445","journal-title":"Anticancer Drugs"},{"key":"399_CR28","first-page":"111","volume":"7","author":"GC Nikou","year":"1994","unstructured":"Nikou GC et al (1994) Octreotide administration and gut hormone levels in patients with chemotherapy-induced diarrhea. Hell J Gastroenterol 7:111\u2013114","journal-title":"Hell J Gastroenterol"},{"issue":"4","key":"399_CR29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s005200000220","volume":"9","author":"V Barbounis","year":"2001","unstructured":"Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9(4):258\u2013260","journal-title":"Support Care Cancer"},{"issue":"1","key":"399_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000227313","volume":"51","author":"S Cascinu","year":"1994","unstructured":"Cascinu S, Fedeli A, Fedeli SL, Catalano G (1994) Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 51(1):70\u201373","journal-title":"Oncology"},{"issue":"5","key":"399_CR31","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(19930901)72:5<1543::AID-CNCR2820720509>3.0.CO;2-Z","volume":"72","author":"NJ Petrelli","year":"1993","unstructured":"Petrelli NJ, Rodriguez-Bigas M, Rustum Y, Herrera L, Creaven P (1993) Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 72(5):1543\u20131546","journal-title":"Cancer"},{"issue":"1","key":"399_CR32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00001622-199801000-00010","volume":"10","author":"K Oberg","year":"1998","unstructured":"Oberg K (1998) Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10(1):58\u201365","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"399_CR33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1010-7940(02)00055-6","volume":"21","author":"PL Filosso","year":"2002","unstructured":"Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O (2002) Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 21(5):913\u2013917","journal-title":"Eur J Cardiothorac Surg"},{"issue":"Suppl 3","key":"399_CR34","first-page":"III15","volume":"50","author":"MJ Farthing","year":"2002","unstructured":"Farthing MJ (2002) Novel targets for the control of secretory diarrhoea. Gut 50(Suppl 3):III15\u2013III18","journal-title":"Gut"},{"issue":"4","key":"399_CR35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","volume":"23","author":"S Ricci","year":"2000","unstructured":"Ricci S, Antonuzzo A, Galli L et al (2000) Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23(4):412\u2013415","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"399_CR36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","volume":"151","author":"SV Welin","year":"2004","unstructured":"Welin SV, Janson ET, Sundin A et al (2004) High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151(1):107\u2013112","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"399_CR37","first-page":"349","volume":"61","author":"RR Warner","year":"1994","unstructured":"Warner RR, Mani S, Profeta J, Grunstein E (1994) Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 61(4):349\u2013355","journal-title":"Mt Sinai J Med"},{"issue":"3","key":"399_CR38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1191\/0269216303pm698oa","volume":"17","author":"K Pistevou-Gombaki","year":"2003","unstructured":"Pistevou-Gombaki K, Eleftheriadis N, Plataniotis GA, Sofroniadis I, Kouloulias VE (2003) Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire. Palliat Med 17(3):257\u2013262","journal-title":"Palliat Med"},{"issue":"11","key":"399_CR39","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.1997.15.11.3350","volume":"15","author":"C Ippoliti","year":"1997","unstructured":"Ippoliti C, Champlin R, Bugazia N et al (1997) Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 15(11):3350\u20133354","journal-title":"J Clin Oncol"},{"issue":"9","key":"399_CR40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1700965","volume":"20","author":"EI Wasserman","year":"1997","unstructured":"Wasserman EI, Hidalgo M, Hornedo J, Cort\u00e9s-Funes H (1997) Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. Bone Marrow Transplant 20(9):711\u2013714","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"399_CR41","first-page":"873","volume":"25","author":"C Ippoliti","year":"1998","unstructured":"Ippoliti C, Neumann J (1998) Octreotide in the management of diarrhea induced by graft versus host disease. Oncol Nurs Forum 25(5):873\u2013878","journal-title":"Oncol Nurs Forum"},{"issue":"9155","key":"399_CR42","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0140-6736(05)76666-6","volume":"353","author":"G Nordesj\u00f6-Haglund","year":"1999","unstructured":"Nordesj\u00f6-Haglund G, L\u00f6nnqvist B, Lindberg G, Hellstr\u00f6m-Lindberg E (1999) Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation. Lancet 353(9155):846","journal-title":"Lancet"},{"issue":"2","key":"399_CR43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00002030-199302000-00010","volume":"7","author":"R Manfredi","year":"1993","unstructured":"Manfredi R, Vezzadini P, Costigliola P, Ricchi E, Fanti MP, Chiodo F (1993) Elevated plasma levels of vasoactive intestinal peptide in AIDS patients with refractory idiopathic diarrhoea: effects of treatment with octreotide. AIDS 7(2):223\u2013226","journal-title":"AIDS"},{"issue":"Suppl 1","key":"399_CR44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000201073","volume":"54","author":"M Moroni","year":"1993","unstructured":"Moroni M, Esposito R, Cernuschi M, Franzetti F, Carosi GP, Fiori GP (1993) Treatment of AIDS-related refractory diarrhoea with octreotide. Digestion 54(Suppl 1):30\u201332","journal-title":"Digestion"},{"issue":"2","key":"399_CR45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0304-3959(94)00267-I","volume":"61","author":"S Mercadante","year":"1995","unstructured":"Mercadante S (1995) Octreotide in the treatment of diarrhoea induced by coeliac plexus block. Pain 61(2):345\u2013346","journal-title":"Pain"},{"issue":"5","key":"399_CR46","first-page":"228","volume":"29","author":"M Gray","year":"2002","unstructured":"Gray M, Jacobson T (2002) Are somatostatin analogues (octreotide and lanreotide) effective in promoting healing of enterocutaneous fistulas? J Wound Ostomy Continence Nurs 29(5):228\u2013233","journal-title":"J Wound Ostomy Continence Nurs"},{"issue":"4","key":"399_CR47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1444-0903.2001.00190.x","volume":"32","author":"S Gibson","year":"2002","unstructured":"Gibson S, Strutt R, Chye R (2002) Managing a malignant orocutaneous fistula: stem the tide with octreotide? Intern Med J 32(4):191\u2013192","journal-title":"Intern Med J"},{"issue":"5","key":"399_CR48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/07357909909032873","volume":"17","author":"S Ayache","year":"1999","unstructured":"Ayache S, Wadleigh RG (1999) Treatment of a malignant enterocutaneous fistula with octreotide acetate. Cancer Invest 17(5):320\u2013321","journal-title":"Cancer Invest"},{"issue":"8691","key":"399_CR49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0140-6736(90)90861-X","volume":"335","author":"RD Penn","year":"1990","unstructured":"Penn RD, Paice JA, Kroin JS (1990) Intrathecal octreotide for cancer pain. Lancet 335(8691):738","journal-title":"Lancet"},{"issue":"1","key":"399_CR50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3959(92)90182-B","volume":"49","author":"RD Penn","year":"1992","unstructured":"Penn RD, Paice JA, Kroin JS (1992) Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain 49(1):13\u201319","journal-title":"Pain"},{"issue":"1","key":"399_CR51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0885-3924(94)90144-9","volume":"9","author":"F Conno De","year":"1994","unstructured":"De Conno F, Saita L, Ripamonti C, Ventafridda V (1994) Subcutaneous octreotide in the treatment of pain in advanced cancer patients. J Pain Symptom Manage 9(1):34\u201338","journal-title":"J Pain Symptom Manage"},{"issue":"5C","key":"399_CR52","first-page":"4039","volume":"20","author":"S Befon","year":"2000","unstructured":"Befon S, Mystakidou K, Lyra M, Tubanakis N, Vlahos L (2000) Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels. Anticancer Res 20(5C):4039\u20134046","journal-title":"Anticancer Res"},{"issue":"2","key":"399_CR53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1507\/endocrj.52.277","volume":"52","author":"M Katai","year":"2005","unstructured":"Katai M, Sakurai A, Inaba H, Ikeo Y, Yamauchi K, Hashizume K (2005) Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor. Endocr J 52(2):277\u2013280","journal-title":"Endocr J"},{"issue":"5","key":"399_CR54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1191\/026921699677473561","volume":"13","author":"W Cairns","year":"1999","unstructured":"Cairns W, Malone R (1999) Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 13(5):429\u2013430","journal-title":"Palliat Med"},{"issue":"2","key":"399_CR55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hon.710","volume":"21","author":"J Evans","year":"2003","unstructured":"Evans J, Clark MF, Mincher L, Varney VA (2003) Chylous effusions complicating lymphoma: a serious event with octreotide as a treatment option. Hematol Oncol 21(2):77\u201381","journal-title":"Hematol Oncol"},{"issue":"3","key":"399_CR56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1072-7515(02)01757-X","volume":"196","author":"P Carcoforo","year":"2003","unstructured":"Carcoforo P, Soliani G, Maestroni U et al (2003) Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial. J Am Coll Surg 196(3):365\u2013369","journal-title":"J Am Coll Surg"},{"issue":"3","key":"399_CR57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2265.1997.1090921.x","volume":"46","author":"CS Mantzoros","year":"1997","unstructured":"Mantzoros CS, Suva LJ, Moses AC, Spark R (1997) Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour. Clin Endocrinol (Oxf) 46(3):373\u2013375","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"399_CR58","first-page":"343","volume":"23","author":"E Shiba","year":"1996","unstructured":"Shiba E, Inoue T, Akazawa K, Takai S (1996) Somatostatin analogue treatment for malignant hypercalcemia associated with advanced breast cancer. Gan To Kagaku Ryoho 23(3):343\u2013347","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"399_CR59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W et al (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17(2):600\u2013606","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-007-0399-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-007-0399-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-007-0399-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T19:33:28Z","timestamp":1737920008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-007-0399-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,7]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s00520-007-0399-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,7]]}}}